HGHuybert Groenendaal

Huybert Groenendaal

*This is an algorithmically generated author record based on publicly available information.

Huybert Groenendaal has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Economic costs of liver abscesses in U.S. beef feedlot cattle: a comprehensive economic analysis

    by Daniel D Taylor, Huybert Groenendaal, Paul S Morley, Francisco Zagmutt

    Liver abscesses (LA) cause significant economic losses in U.S. beef feedlot cattle through a variety of production and performance effects. This research estimated annual economic losses secondary to LA in U.S. beef feedlot cattle using a stochastic simulation model that was based on data from the literature, economic data, and expert opinion. LA prevalence was estimated for 4 U.S. regions and 4 cattle types along with their combinations. Economic losses were estimated by combining modeling results from individual loss categories related to feed efficiency, liver, offal, and trim loss, effects on carcass quality, and processing delays. Losses were also estimated under different antimicrobial use and production scenarios. We estimated that LA result in annual losses of $256M (95% Credible interval: $162M to $378M) to the U.S. beef industry. Decreased average daily gain (ADG) and a lower dressing percentage prior to trimming accounted for nearly half (48.6%) of these losses, while liver and offal condemnation and excess trimming comprised approximately 40% of all losses. Processing delays were estimated to contribute approximately 5% of the total losses. There was also substantial variation in the estimated prevalence and impacts of LA by region and cattle type, with beef-dairy crossbred (BD) cattle in the Western region experiencing the highest economic losses per animal. Scenario analyses predicted that eliminating the use of tylosin may nearly double LA prevalence and associated economic costs while transitioning all beef cattle born on dairies from Holsteins to BD cattle would only slightly increase overall losses. Our findings show that LA cause substantial, yet uncertain, losses to the U.S. beef feedlot industry. The results also emphasize the need for additional research to elucidate the effect of LA on feed efficiency and to improve LA prevention strategies, which could enhance animal health and productivity as well as industry sustainability.


  • Open Access

    Expert opinion on the identification, risk assessment, and mitigation of microorganisms and parasites relevant to xenotransplantation products from pigs

    by Huybert Groenendaal, Solenne Costard, Reid Ballard, Stephen Bienhoff, Diana C. Challen, Brandon J. Dominguez, Douglas R. Kern, Dan Miller, Jeske Noordergraaf, Larisa Rudenko, et al.

    Xenotransplantation has the potential to address shortages of organs available for clinical transplantation, but concerns exist regarding potential risks posed by porcine microorganisms and parasites (MP) to the health of human recipients. In this study, a risk‐based framework was developed, and expert opinion was elicited to evaluate porcine MP based on swine exposure and risk to human health. Experts identified 255 MP to include in the risk assessment. These were rated by experts for five criteria regarding potential swine exposure in the USA and human health risks. MP were subsequently categorized into three risk mitigation groups according to pre‐defined rules: disqualifying porcine MP (due to their pathogenic potential, n = 130); non‐disqualifying porcine MP (still relevant to consider for biosecurity or monitoring efforts, n = 40); and alert/watch list (not reported in the USA or MP not in swine, n = 85). Most disqualifying (n = 126) and non‐disqualifying (n = 36) porcine MP can effectively be eliminated with high biosecurity programs. This approach supports surveillance and risk mitigation strategies for porcine MP in swine produced for xenotransplantation, such as documentation of freedom from porcine MP, or use of porcine MP screening, monitoring, or elimination options. To the authors’ knowledge, this is the first effort to comprehensively identify all relevant porcine MP systematically and transparently evaluate the risk of infection of both donor animals and immunosuppressed human recipients, and the potential health impacts for immunosuppressed human recipients from infected xenotransplantation products from pigs.


  • Open Access

    Sleeping with the enemy: Maintaining ASF-free farms in affected areas

    by Huybert Groenendaal, Solenne Costard, Francisco J. Zagmutt, Andres M. Perez

    African Swine Fever (ASF) continues to spread worldwide, with very limited eradication success in countries where the disease affects domestic pig populations. Various biosecurity tools exist to reduce the on-farm risk incursion of ASF and other diseases. However, their focus on overall biosecurity scores and benchmarking results in recommendations that are not always cost-effective. We propose to apply a risk analysis approach that actively involves farmers and farmworkers in identifying their weakest links in biosecurity and corresponding mitigation efforts. Furthermore, the approach's focus on describing and understanding pathways of introduction and/or spread specific to individual farms creates buy-in from producers for investing in biosecurity measures and improving compliance.


  • Open Access

    Time Series Models

    by Dale E. Lehman, Huybert Groenendaal

  • Open Access

    Modeling Relationships

    by Dale E. Lehman, Huybert Groenendaal

  • Open Access

    Practical Spreadsheet Modeling Using @Risk

    by Dale E. Lehman, Huybert Groenendaal

  • Open Access

    Cost-benefit analysis of vaccination against Mycobacterium avium ssp. paratuberculosis in dairy cattle, given its cross-reactivity with tuberculosis tests

    by Huybert Groenendaal, Francisco J. Zagmutt, Elisabeth A. Patton, Scott J. Wells

    Johne's disease (JD), or paratuberculosis, is a chronic enteric disease of ruminants, caused by infection with Mycobacterium avium ssp. paratuberculosis (MAP). Johne's disease causes considerable economic losses to the US dairy industry, estimated to be over $200 million annually. Available control strategies include management measures to improve calf hygiene, test-and-cull strategies, and vaccination. Although the first 2 strategies have shown to reduce the prevalence of MAP, they require dedicated and long-term efforts from dairy producers, with often relatively slow progress. As a result, uptake of both strategies has not been as wide as expected given the economic benefits especially of improved hygiene. Vaccination has also been found to reduce the prevalence and economic losses of JD, but most economic estimates have been based on simulation of hypothetical vaccines. In addition, if an animal is vaccinated, cross-reactivity between MAP antibodies and bovine tuberculosis (BTB) antigens may occur, decreasing the specificity of BTB tests. Therefore, MAP vaccination would cause additional indirect costs to the BTB surveillance and control program. The objective of the present study was to use data from a MAP vaccine trial together with an epidemiologic and economic model to estimate the direct on-farm benefits of MAP vaccination and to estimate the indirect costs of MAP vaccination due to the cross-reactivity with BTB tests. Direct economic benefits of MAP vaccination were estimated at $8.03 (90% predictive interval: -$25.97 to $41.36) per adult animal per year, all accruing to the dairy producers. This estimate is likely an underestimation of the true direct benefits of MAP vaccination. In addition, indirect economic costs due to cross-reactivity were $2.14 per adult animal per year, making MAP vaccination economically attractive. Only in regions or states with a high frequency of BTB testing (because of, for example, Mycobacterium bovis outbreaks in a wild deer population) and areas where typically small groups of animals are BTB tested would MAP vaccination not be economically attractive.


  • Treatment of Advanced Parkinsonʼs Disease in the United States

    by Huybert Groenendaal, Marcy L. Tarrants, Christophe Armand

    Background: As Parkinson’s disease (PD) progresses, patients and their families experience substantial health and economic burdens. Because motor fluctuations (also called ‘off-time’) are linked to poor quality of life and higher healthcare costs, minimizing off-time is an effective strategy for reducing costs associated with PD. Objective: To assess the cost utility of rasagiline or entacapone as adjunctive therapies to levodopa versus levodopa/carbidopa/entacapone (LCE) versus standard levodopa monotherapy in patients with advanced PD and motor fluctuations in the US. Methods: A 2-year stochastic Markov model was utilized to examine the cost effectiveness of treatments of advanced PD. The model assumed that patients transition health status every 4 months. Transition probabilities, including uncertainties, were estimated from clinical trial data. Medical costs, daily drug costs and utility weights were obtained from published literature. Results: Over 2 years, all therapy options showed greater effectiveness than levodopa alone. Rasagiline + levodopa and LCE were cost saving from a payor perspective, while entacapone + levodopa was cost saving from a societal perspective. Mean benefits over 2 years were 0.12 (90% credibility interval [CI] 0.07, 0.18) additional quality-adjusted life-years (QALYs) for rasagiline + levodopa, entacapone + levodopa and LCE, 5.08 (90% CI 3.87, 6.28) additional months with ≤25% off-time for rasagiline + levodopa and 4.85 (90% CI 3.63, 6.06) additional months with ≤25% off-time for entacapone + levodopa and LCE versus levodopa alone. Conclusion: From a payor perspective, rasagiline + levodopa and LCE were dominant therapies over levodopa monotherapy, while entacapone+ levodopa was effective at a higher cost. With no additional cost over a 2-year period, rasagiline + levodopa presents a valuable alternative to entacapone + levodopa, LCE and levodopa monotherapy in the treatment of advanced PD patients. Results from this cost-utility model and prior adjunctive clinical data provide ongoing support for the adjunctive use of rasagiline in advanced PD patients with motor fluctuations.